Q3 2024 Oncolytics Biotech Inc Earnings Call Transcript
Key Points
- Oncolytics Biotech Inc (ONCY) reported promising final data from the Bracelet One breast cancer study, showing substantial improvements in progression-free survival and overall survival when combining their therapeutic agent with paclitaxel.
- The company is planning a registration-enabling Phase II study for HR-positive, HER2-negative metastatic breast cancer, aiming for accelerated approval based on positive clinical benefits observed.
- Oncolytics Biotech Inc (ONCY) is advancing its gastrointestinal cancer program, with promising efficacy signals in pancreatic cancer, supported by collaborations with GCAR and a $5 million grant from the Pancreatic Cancer Action Network.
- The company has ongoing collaborations with major pharmaceutical companies like Roche and Pfizer, indicating strong industry interest and potential for strategic partnerships.
- Financially, Oncolytics Biotech Inc (ONCY) has managed to decrease its net cash used in operating activities compared to the previous year, reflecting efficient cash management as they ramp up efforts for registration.
- The company faces uncertainties and risks related to the execution of their clinical trials and the potential for delays in achieving regulatory approvals.
- Oncolytics Biotech Inc (ONCY) reported a net loss of $9.5 million for the third quarter of 2024, indicating ongoing financial challenges.
- There is no guarantee of regulatory approval, as the FDA requires compelling data, and the company acknowledges that the FDA will not commit to approval before seeing final results.
- The company is still in the early stages of engaging potential partners for their breast cancer program, with significant outreach efforts planned for the future.
- Enrollment timelines for their pancreatic cancer trial remain uncertain, as they need to finalize the protocol and seek FDA guidance, which could impact the speed of trial progression.
Good afternoon and welcome to an Oncolytics byte third quarter, 2024 conference call.
All participants are in a listen-only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to John Patton, Director of Investor Relations and Communication. Please go ahead.
Thank you operator and thank you all for joining us. After remarks from company management, we will open the call for Q&A as a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of Peller rep including statements regarding the company's mission strategy and milestones, the company's belief as to the potential and mechanism of action of Peller rep as a cancer therapeutic. Our potential registrational opportunities with plar rep and our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
